Now Available from CCO Hepatitis
 |
CCO CONFERENCE COVERAGE
Online Coverage of the Hepatitis Meeting in Boston
Stay current with the latest treatment information and options presented in Boston. CCO's Conference Coverage will include Capsule Summaries of important data as well as audio expert highlights, a CCO original downloadable slideset, and a CME/CE-certified Expert Analysis. Click Here
|
Treatment Update
This treatment update explores the latest data on available therapeutic options and management strategies for the approximately 40% to 60% of patients infected with genotype 1 HCV who experience treatment failure to frontline therapy.
Now Available!
CME-Certified Interactive Virtual Presentation:
Downloadable CCO Slideset:
Journal Options
Stay up to date with the current medical literature through a CME-certified learning module including CCO’s Capsule Summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.
Topics include:
- Genetic Link to Therapeutic Response Identified Among HCV-Infected Individuals
- Peginterferon alfa-2a and alfa-2b Produce Similar SVR Rates
- Weight Loss Can Alter HCV Liver Disease Progression
- Metabolic Factors That Predict RVR to Peginterferon/Ribavirin in HCV Patients
- Short-Duration Therapy for Genotype 1 Treatment-Naive HCV Patients
- High ALT and HBeAg-Negative, HBsAg-Positive Disease
- Chronic Hepatitis B: A Predictor of Long-term Response to Peginterferon Identified
- Lactulose Prophylaxis for the Prevention of Hepatic Encephalopathy Recurrence
Treatment Update
In this new Treatment Update, CCO’s expert faculty members assess the scale of the current and estimated future HCV epidemic, review the latest data from recent and ongoing clinical trials investigating the use of targeted antiviral therapies (STAT-Cs) for the management of HCV infection, and explore how these findings may impact future HCV treatment paradigms.
Now Available!
CME-Certified Interactive Virtual Presentation:
 |
Smoother Waters Ahead? New Directions in the Management of HCV Stefan Zeuzem, MD, provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with HCV infection in this Interactive Virtual Presentation. He also reviews data from recent and ongoing clinical trials of STAT-C agents in late clinical development and their potential impact on HCV management. Participants are polled on practical issues in current and near future HCV treatments and can compare their results to their colleagues. |
Downloadable CCO Slideset:
 |
Smoother Waters Ahead? New Directions in the Management of HCV Downloadable slideset for use in your own noncommercial presentations highlights key data on the magnitude of the HCV epidemic and data from recent ongoing clinical trials and the potential impact on HCV management of STAT-C agents in late clinical development. |
Downloadable Worksheets:
 |
Genotype 1/4 HCV Treatment Monitoring Chart This worksheet allows you to conveniently record HCV RNA and key laboratory measurements that should be monitored before, during, and after HCV therapy of genotype 1/4 patients. |
 |
Genotype 2/3 HCV Treatment Monitoring Chart This worksheet allows you to conveniently record HCV RNA and key laboratory measurements that should be monitored before, during, and after HCV therapy of genotype 2/3 patients. |
Treatment Update
This treatment update delivers an overview of current best practices for screening and diagnosing patients with chronic hepatitis B and provides a detailed analysis of the safety, efficacy, durability, and potency of approved state-of-the-art options for initiating HBV treatment.
Now Available!
Downloadable CCO Slideset:
Downloadable Worksheet:
CCO Official Conference Coverage
CCO's official coverage of the 2009 Annual Meeting of the American Association for the Study of Liver Diseases includes Capsule Summaries of key presentations, as well as Expert Analyses, Slides, and audio Expert Highlights that focus on key issues highlighted at the conference.
Updates in HCV Treatment Michael P. Manns, MD; David R. Nelson, MD; and Tram T. Tran, MD
Management of HBV, Advanced Liver Disease, and Other Related Complications Robert G. Gish, MD
Now Available!
CME-Certified Expert Analysis:
   |
Updates in HCV Treatment In this Expert Analysis, Michael P. Manns, MD; David R. Nelson, MD; and Tram T. Tran, MD, provide an in-depth review of the most important new data presented at the 2009 AASLD meeting on the management of patients with chronic HCV infection. |
Downloadable CCO Slideset:
 |
Highlights From AASLD 2009 Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease. |
Annual Update
Clinical Care Options' Hepatitis Annual Update offers the latest information across a wide range of issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME/CE-certified educational modules and a downloadable slideset that are now available on the CCO Web site:
Now Available!
CME/CE-Certified Modules:
 |
Benefits and Risks of HBV Therapy Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks for hepatitis B management using currently available therapeutic agents. |
 |
Update on Investigational HCV Agents Jean-Michel Pawlotsky, MD, PhD, discusses how insights into the virology of HCV have unraveled several targets for potential novel therapeutics. |
Downloadable PowerPoint Slideset:
 |
Hepatitis Annual Update 2009 Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis. |
Management Series
This comprehensive Management Series provides an in-depth analysis of the updated 2009 AASLD recommendations for diagnosing and managing treatment-naive and treatment-experienced patients with chronic hepatitis C. Specific strategies for optimizing therapy according to HCV genotype and on-treatment virologic response are discussed as are tailored approaches for managing special patient populations. Now Available!
CME-Certified Interactive Virtual Presentations:

|
Hepatitis C Testing and Counseling: The Gateway to Treatment David L. Thomas, MD, MPH, discusses how risk-based testing can help identify the large population of undiagnosed patients infected with hepatitis C. |

|
Initial HCV Management, Treatment and Monitoring John G. McHutchison, MD, FRACP, provides an overview of the AASLD 2009 guideline update on the initial management, treatment, and monitoring of patients with hepatitis C. |

|
Management and Treatment of Special Populations of HCV-Infected Patients Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. | Downloadable CCO Slidesets:
 |
Hepatitis C Testing and Counseling: The Gateway to Treatment In this downloadable slideset, David L. Thomas, MD, MPH, discusses the importance of HCV testing, as it is the first step in the management and treatment of HCV infection. |
 |
Initial HCV Management, Treatment and Monitoring In this downloadable slideset, John G. McHutchison, MD, FRACP, provides an update on the initial management, treatment, and monitoring of patients with hepatitis C. |
 |
Management and Treatment of Special Populations of HCV-Infected Patients In this downloadable slideset, Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. | CME-Certified Interactive Case Challenges:

|
Management of a Genotype 1 HCV Patient in a Methadone Maintenance Program David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program. |

|
Management of an HCV-Infected Compensated Cirrhotic Patient With Moderate Alcohol Use Guy Neff, MD, MBA, discusses the challenging management decisions involved in treating an HCV-infected compensated cirrhotic patient with moderate alcohol use. |

|
Management of an HCV-Infected Black Woman With Delayed Diagnosis and Treatment Maribel Rodriguez-Torres, MD, CPI, discusses the management of an HCV-infected black woman with significant liver disease due to delayed diagnosis and treatment. |

|
Initial HCV Therapy in a Patient With Mild Depression Join K. Rajender Reddy, MD, in choosing the optimal treatment strategies for a patient with chronic HCV infection and a history of depression. |

|
HCV Treatment Candidacy in an HCV/HIV-Coinfected Patient Receiving HIV Therapy Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV. |

|
Retreatment in a Patient Failing Initial HCV Therapy Samuel B. Ho, MD, presents a case patient who showed an initial response to peginterferon/ribavirin therapy but did not achieve sustained virologic response. | Downloadable Worksheet:
Journal Options
Stay up to date with the current medical literature through a CME-certified learning module and CCO’s capsule summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.
Topics include:
- Telaprevir for chronic HCV genotype 1 infection
- Prolonged HCV therapy with low-dose peginterferon
- HCC in hepatitis C–related advanced liver disease
- Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin: DIRECT results
- Chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, ribavirin
- Tenofovir vs adefovir for chronic hepatitis B
- Early serum HBsAg drop and SVR in HBeAg-negative patients
- Rifaximin for hepatic encephalopathy
- Effect of fatigue on driving skills in hepatic encephalopathy patients
Treatment Update
CCO’s expert faculty members discuss the latest clinical data and best practices for selecting optimal initial HBV therapy, including a review of different initial management strategies for HBeAg-positive and HBeAg-negative patients with chronic HBV infection.
Now Available!
CME-Certified Module:
 |
HBV Treatment: What to Start? Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection. |
Downloadable CCO Slideset:
 |
HBV Treatment: What to Start? Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own noncommercial presentations. |
CME-Certified Interactive Case Challenges:
CCO Conference Coverage
CCO's coverage of the 2009 Annual Meeting of the European Association for the Study of the Liver includes Capsule Summaries of key presentations, as well as Expert Analyses, and audio Expert Highlights that focus on key issues highlighted at the conference.
CME-Certified Expert Analyses:
Treatment Update
Expert faculty members review and explore regional and systemic treatment strategies for the clinical management of patients with hepatocellular carcinoma.
Now Available!
Video Panels:
More Treatment Update
-
Hepatitis C Advanced Practice Curriculum 2009 Through 3 Interactive Virtual Presentations, CCO’s expert faculty members review recent data and discuss critical aspects of HCV disease management, including the importance of patient quality of life, topics pertaining to patient retreatment, and strategies for minimizing cirrhosis and liver disease progression.
-
-
-
-
-
-
-
More CCO Independent Conference Coverage
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
More Management Series
More Interactive Case Challenges
|
Browse Hepatitis
New Data
Slidesets
Cases
Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.
Click here for more cases.
Self-Assessment
Tools
|